EI
MBRX icon

EFG International’s Moleculin Biotech MBRX Stock Holding History

EFG International’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$994 Hold
434
– – ﹤0.01% 1022
2025
Q4 		$1.44K Buy
+434
New +$4.04K ﹤0.01% 851

Other funds holding MBRX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWPS
Pinnacle Wealth Planning Services Mansfield, Ohio $968M AUM 19.1% 1-Year Est. Return

EFG International's MBRX Position: Q1 2026 in Review

EFG International held its Moleculin Biotech (MBRX) position steady in Q1 2026 at 434 shares worth $994. The position accounts for ﹤0.01% of the portfolio, ranked #1022.

EFG International first reported a position in MBRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.44K in Q4 2025. 20 funds tracked by Wall St. Rank hold MBRX as of Q1 2026.

  • EFG International held 434 shares of Moleculin Biotech worth $994 as of Q1 2026.
  • EFG International left its Moleculin Biotech share count unchanged in Q1 2026.
  • Moleculin Biotech made up ﹤0.01% of EFG International's portfolio in Q1 2026, its #1022 holding.
  • EFG International first reported a position in Moleculin Biotech in Q4 2025 and has held it in 2 quarters since.
  • EFG International's Moleculin Biotech position peaked at $1.44K in Q4 2025.
  • 20 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2026.

Based on EFG International's 13F filing for Q1 2026, filed 15 May 2026.